NIKKEI 225
27,476.87 +91.62 (+0.33%) HANG SENG
19,567.69 -347.99 (-1.75%) CRUDE OIL
72.89 +3.63 (+5.24%) GOLD FUTURES
1,957.70 +3.90 (+0.20%) DOW
32,432.08 +194.55 (+0.60%) BTC-GBP
22,104.70 -542.12 (-2.39%)
Amneal Pharmaceuticals, Inc. (AMRX)
After hours:
| Previous close | 1.3300 |
| Open | 1.3400 |
| Bid | 1.3000 x 2900 |
| Ask | 1.3100 x 3100 |
| Day's range | 1.2600 - 1.3600 |
| 52-week range | 1.2600 - 4.6000 |
| Volume | |
| Avg. volume | 1,115,726 |
| Market cap | 391.635M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | 2.11 |
| EPS (TTM) | 0.6100 |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.42 |
- Zacks
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
BRIDGEWATER, N.J., March 02, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and is used in the treatment of a known or suspected opioid overdose emergency.
- Business Wire
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
BRIDGEWATER, N.J., March 02, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") announced its results today for the fourth quarter and full year ended December 31, 2022.
